Nutex Health Inc.

For the period ended Dec 31, 2024. Filed Mar 31, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 31, 2025

NUTX$186.25-4.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows


· · Year ended December 31,
	2024		2023		2022
Cash flows from operating activities:
Net income (loss)		$95,271,921		$(43,423,715)		$(432,739,618)
Adjustment to reconcile net income (loss) to net cash from operating activities:
Depreciation and amortization		18,971,972		17,591,572		13,131,374
Impairment of assets		3,887,216		29,082,203		-
Impairment of goodwill		3,197,391		1,139,297		398,135,038
Derecognition of goodwill		453,017		-		-
Loss on warrant liability		1,608,973		-		-
Stock-based compensation expense		16,631,898		2,835,971		189,581
Rescission of warrant exercise expense		-		-		561,651
Deferred tax (benefit) expense		(13,132,990)		(5,707,323)		4,996,209
Debt accretion expense		1,042,663		1,209,981		1,952,829
Loss on lease termination		-		58,210		-
Non-cash lease expense		(381,035)		131,582		64,143
Changes in operating assets and liabilities:
Accounts receivable		(173,956,924)		(969,761)		56,622,133
Accounts receivable - related party		549,879		(3,613,885)		1,454,934
Inventories		540,770		142,701		(719,107)
Prepaid expenses and other current assets		(7,021,010)		(817,297)		(1,419,139)
Accounts payable		(8,682,179)		(4,715,101)		10,018,100
Accounts payable - related party		(2,037,059)		2,466,536		(329,155)
Accrued arbitration expenses		47,741,815		-		-
Accrued income tax expense		25,989,262		-		-
Accrued expenses and other current liabilities		12,478,227		5,845,481		(1,311,865)
Net cash from operating activities		23,153,807		1,256,452		50,607,108

Cash flows from investing activities:
Acquisitions of property and equipment		(2,303,897)		(9,496,832)		(14,632,414)
Acquired cash in reverse acquisition with Clinigence		-		-		12,716,228
Cash related to sale of business		(361,325)		-		-
Payments for acquisitions of businesses, net of cash acquired		-		(703,893)		-
Cash related to deconsolidation of Real Estate Entities		-		(1,039,157)		(2,421,212)
Net cash from investing activities		(2,665,222)		(11,239,882)		(4,337,398)

Cash flows from financing activities:
Proceeds from lines of credit		2,261,743		2,340,911		2,623,479
Proceeds from notes payable		7,014,999		16,952,905		815,881
Proceeds from convertible notes		-		4,909,864		-
Repayments of lines of credit		(2,079,390)		(1,592,714)		(72,055)
Repayments of notes payable		(9,969,391)		(16,479,512)		(7,237,094)
Repayments of finance leases		(4,628,083)		(3,484,683)		(1,721,224)
Proceeds from common stock issuance, net issuance costs		9,202,500		-		-
Rescission of warrant exercise		-		-		(588,042)
Proceeds from exercise of warrants		2,373,336		-		4,119,141
Proceeds from exercise of options		-		-		644,974
Members' contributions		3,353,023		298,032		4,513,867
Members' distributions		(6,437,966)		(5,214,581)		(51,231,657)
Net cash from financing activities		1,090,771		(2,269,778)		(48,132,730)
Net change in cash and cash equivalents		21,579,356		(12,253,208)		(1,863,020)
Cash and cash equivalents - beginning of the year		22,002,056		34,255,264		36,118,284
Cash and cash equivalents - end of the year		$43,581,412		$22,002,056		$34,255,264

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.